US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 37.500
  • -0.480-1.26%
Trading Jul 22 11:08 ET
4.55BMarket Cap-10932P/E (TTM)

Apellis Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Apellis Pharmaceuticals Earnings Date

Currency: USD

Period

Q2 FY2024 Estimates

Aug 1, 2024

Revenue(YoY)

194.06M

+104.34%
EPS(YoY)

-0.30

+71.05%
Analyst Rating

Strong Buy

Jul 22, 2024

Apellis Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 17 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 217.383M--
Aug 1, 20242024/Q2-- / 194.055M--
May 7, 20242024/Q1172.325M / 164.259M--
Feb 27, 20242023/Q4146.377M / 143.592M--
Nov 1, 20232023/Q3110.399M / 99.054M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 217.383M--
Aug 1, 20242024/Q2-- / 194.055M--
May 7, 20242024/Q1172.325M / 164.259M--
Feb 27, 20242023/Q4146.377M / 143.592M--
Nov 1, 20232023/Q3110.399M / 99.054M--

Unlock Free Earnings Estimates

Apellis Pharmaceuticals Earnings Reports

  • Apellis Pharmaceuticals | 10-Q: Quarterly report

    May 7 07:04 ET

  • Apellis Pharmaceuticals | 10-K/A: Annual report (Amendment)

    Feb 29 17:15 ET

  • Apellis Pharmaceuticals | 10-K: Annual report

    Feb 27 07:05 ET

  • Apellis Pharmaceuticals | 10-Q: Q3 2023 Earnings Report

    Nov 1, 2023 07:02 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 22, 2024

    Strong Buy

    • Buy

      78.57%

    • Hold

      21.43%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg
    Concept Gene Editing
    Gene Editing
    Intraday+0.56%